Table 3.
PC-QOL scores and laboratory and FEV1% predicted results on days 1 and 14
|
Amoxicillin–clavulanate |
Azithromycin |
Placebo |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N* | Day 1 | Day 14 | Change from day 1 to day 14 | Difference in change versus placebo | N* | Day 1 | Day 14 | Change from day 1 to day 14 | Difference in change versus placebo | N* | Day 1 | Day 14 | Change from day 1 to day 14 | |
| PC-QOL score | 53 | 4·6 (2·9 to 5·7) | 6·5 (5·2 to 7·0) | 0·8 (0·2 to 2·1) | 0·1 (−0·6 to 0·7) | 53 | 4·1 (3·2 to 5·2) | 6·5 (5·0 to 6·9) | 1·3 (0·4 to 2·3) | 0·6 (0·0 to 1·3) | 54 | 4·6 (3·7 to 5·7) | 5·6 (4·4 to 6·8) | 0·7 (0·1 to 1·5) |
| White blood cell count, × 109/L | 15 | 9·3 (6·8 to 11·2) | 8·3 (6·4 to 11·2) | 0·1 (−2·4 to 2·5) | −0·8 (−3·6 to 2·0) | 18 | 9·2 (6·7 to 9·8) | 7·8 (7·0 to 12·8) | 0·0 (−0·2 to 0·7) | −0·9 (−4·5 to 2·7) | 7 | 9·0 (7·6 to 10·3) | 8·9 (7·1 to 10·5) | 1·0 (−1·4 to 2·6) |
| C-reactive protein concentration, mg/L | 16 | 2·3 (2·0 to 7·1) | 2·0 (2·0 to 2·0) | −0·4 (−5·6 to 0·2) | 3·7 (−4·6 to 12·0) | 19 | 2·0 (2·0 to 2·2) | 2·0 (2·0 to 2·0) | 0·0 (0·0 to 0·0) | 3·7 (−2·4 to 9·8) | 7 | 5·7 (2·0 to 15·0) | 2·0 (2·0 to 2·0) | −4·2 (−13·0 to 0·0) |
| FEV1% predicted | 9 | 81·0 (73·0 to 89·0) | 90·5 (81·0 to 98·5) | 10·0 (5·0 to 11·0) | 10·0 (3·9 to 16·1) | 13 | 92·0 (76·0 to 98·0) | 94·0 (87·0 to 96·0) | 2·0 (−1·6 to 3·0) | 2·0 (−5·0 to 9·0) | 6 | 86·0 (79·0 to 96·0) | 91·0 (84·0 to 102·0) | 0·0 (−1·0 to 4·0) |
Data are median (IQR), except difference in change versus placebo (reported as median change [95% CI] from regression analyses). PC-QOL=parent cough-specific quality-of-life.
*
Number of participants with paired values available (days 1 and 14).